Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Courses
  4. ESMO Preceptorship on Metastatic Bladder and Kidney Cancer 2024: Lugano

SESSION 5 - Renal Cancer – Part II

Debate: Immune combinations or VEGF/PD1 inhibition as 1st line therapy for advanced clear cell RCC - VEGF/PD1 inhibition

Date

04 Apr 2024

Session

SESSION 5 - Renal Cancer – Part II

Topics

Targeted Therapy

Tumour Site

Renal Cell Cancer

Presenters

V. Grünwald, DE

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.